Mevalonate Kinase Deficiency (MKD)
Mevalonate kinase deficiency (MKD) is a rare metabolic autoinflammatory disorder caused by mutations in the MVK gene. Without enough of this enzyme, the cholesterol biosynthesis pathway is disrupted, pro-inflammatory precursors build up and the body overproduces interleukin-1 beta (IL-1β). The disease takes two main forms: hyper-IgD syndrome (HIDS), the milder form, and mevalonic aciduria (MA), a severe form that affects the nervous system.
At Haute-Derma, we treat MKD not simply as a skin problem but as a systemic disorder that needs care on several levels. Our aim is to break the cycle of prolonged fevers, calm the skin lesions and mouth ulcers, and help patients regain comfort and develop to their full potential.
Our Approach to Treating MKD
Our doctors at Haute-Derma base treatment on correcting the cytokine imbalance behind the disease. MKD fevers are often long and exhausting, so we prioritize controlling inflammation early to prevent permanent tissue damage.
We combine specialized biochemical testing with targeted biologic therapy to build an individualized treatment plan. At Haute-Derma, care covers everything from symptom management to genetic counseling, with a focus on long-term health.
Our MKD care pathway includes:
- Organic acid and enzyme testing to establish the degree of mevalonate kinase deficiency.
- IL-1-blocking biologic therapy to keep recurrent fever episodes under control.
- Dedicated mucosal and skin care for mouth ulcers and rashes.
How We Diagnose MKD at Haute-Derma
MKD symptoms vary widely and are easily mistaken for infection, so Haute-Derma follows a structured diagnostic process:
- Fever pattern analysis: We look for fever episodes lasting 3–7 days, often starting after vaccination, injury or emotional stress.
- Skin and mucosal findings: We check for red papules, hives or purpura together with mouth ulcers (aphthous ulcers) and painful swollen neck glands.
- Urine biochemistry: Urinary mevalonic acid is measured, ideally during an acute fever episode.
- Serum IgD level: We check for raised immunoglobulin D (usually above 100 IU/ml), although not every patient has an elevated level.
- MVK gene sequencing: The gold standard for confirming the mutation and predicting how severe the disease will be.
How Is MKD Treated at Haute-Derma?
We use potent immunomodulating regimens to counter the effects of the faulty metabolic pathway:
- Anti-IL-1 biologics (canakinumab/anakinra): Our first-line choice at Haute-Derma. By blocking excess IL-1β, these drugs bring fever episodes under control quickly and prevent systemic symptoms.
- TNF-alpha inhibitors: In selected cases, an anti-TNF drug may be added to reduce arthritis and persistent skin symptoms.
- Short courses of NSAIDs and corticosteroids: These ease joint and bone pain and fever early on, before the biologic takes full effect.
- Nutritional and metabolic management: Cholesterol and fat-soluble vitamin levels are monitored to keep the body's metabolism in balance.
- Monitoring psychomotor development: In severe forms, we work with neurologists to act early on signs of developmental delay or ataxia.
